Metastatic prostate cancer
|
|
- Cornelia McDonald
- 7 years ago
- Views:
Transcription
1 Metastatic prostate cancer Dr Alison Tree Consultant Clinical Oncologist Royal Marsden Hospital
2 2 Outline of the talk Metastatic prostate cancer scope Castration sensitive disease Castration resistant disease incl. novel therapies Symptom control cord compression, bone mets
3 3 Prostate cancer how big is the problem in the UK? CRUK cancer stats:
4 4 UK incidence and mortality of prostate cancer
5 5 We cure most prostate cancer
6 6 Improvements in survival? 1970s: 70% prostate cancer patients were dead by 5 years 2011: More than 80% survive 5 years Prostate cancer remains the second commonest cause of male cancer death in the UK Many patients with metastatic disease now live 5 years or more
7 7 Androgen dependance Image: Cancer.gov
8 8 But, in the absence of gonadal androgens Ang et al, Br J Cancer 2009
9 9 Metastatic prostate cancer - PSA Grist et al, J Steroid Biochem Mol biol 2014
10 10 Prostate specific antigen Helps sperm to swim Produced in the prostate Not ideal for diagnosing localised prostate cancer Reliable for monitoring metastatic disease
11 11 Common sites of metastases Bone metastases spinal cord compression common Lymph node metastases (esp pelvic and abdomen) End-stage can spread to liver, lungs Very rarely causes brain mets
12 12 Bone scan Multiple bone lesions consistent with metastases Bone only disease relatively common
13 Management algorithms
14 14 Castration
15 15 Androgen dependance Image: Cancer.gov
16 16 All men with metastatic disease (*) Should be on lifelong Androgen deprivation therapy* Dramatic symptom improvement Side effects: hot flushes, fatigue, muscle weakness, emotional lability, erectile dysfunction. Longer term bone mass loss and risk of CVD. Caveats end of life
17 17 How to start ADT Short course anti-androgen tablets (eg Bicalutamide 150mg od) for 3-4 weeks First LHRH analogue injection after 7-14 days of anti-androgen Thereafter LHRHa monthly, 3 monthly or 6 monthly for life Other option: Degarelix LHRH antagonist. No anti-androgen cover required, faster drop in testosterone
18 18 But earlier this year Everything changed
19 19 STAMPEDE MAMS trial design
20 20 Results of STAMPEDE arm C ADT alone (1000) vs ADT+ 6 cycles of docetaxel chemotherapy (around 600 pts) Randomised phase III Trial included locally advanced patients, but next slide is patients presenting with metastatic disease only
21 22 months 22 months prolongation of survival James N et al. J Clin Oncol 33, 2015 (suppl; abstr 5001), ASCO Annual meeting 2015.
22 22 ADT+Docetaxel now standard of care for fit men at first presentation of metastatic disease Often men up to 75 and beyond can manage chemo well Docetaxel 75 mg/m2 once every 3 weeks Febrile neutropenia 12% Fit men = performance status 2 or better
23 23 What are the active agents in CRPC?
24 24 NCCN guidelines for metastatic disease
25 25 Active agents in metastatic castrateresistant prostate cancer part 1 Docetaxel 2.5 months survival advantage over mitoxantrone (Tannock et al 2004) Taxane chemotherapy drug which is given intravenously and works by interfering with cell division. Risks nausea, fatigue, hair loss, neuropathy, VTE, febrile neutropenia
26 26 Active agents in metastatic castrateresistant prostate cancer part 1 Abiraterone post docetaxel 4 months improvement in survival 15.8 vs 11.2 mo (Fizzazi et al 2012) Abiraterone pre chemo 35.3 vs 30.1 mo (Ryan et al 2013, Rathkopft et al, 2014) Abiraterone (Zytiga) is an oral hormonal agent, stops extra gonadal androgen synthesis. Taken with bd Prednisolone. Side effects hypokalaemia, hypertension, liver enzyme derangement.
27 27 Active agents in metastatic castrateresistant prostate cancer- part 2 Enzalutamide pre chemo 32.4 vs 30.2 months (Beer et al, 2014) Enzalutamide post docetaxel: AFFIRM study 5 mo survival advantage 18.4 mo vs 13.6 months (Sher et al 2012 Enzalutamide (Xtandi) is an oral hormonal agent which reduces the action of androgens at the cell surface and within the cell. It is taken one a day without steroids. Side effects fatigue and small risk of seizures
28 28 Active agents in metastatic castrateresistant prostate cancer- part 2 Cabazitaxel post docetaxel TROPIC study de Bono et al vs 12.7 months Cabazitaxel is an intravenous chemotherapy agent. Side effects nausea, fatigue, hair loss, VTE, neutropaenia (+)
29 29 Active agents in metastatic castrateresistant prostate cancer- part 2 Radium 223 (Xofigo) ALSYMPCA study (Parker et al 2013) 14.9 vs 11.3 mo Radium is an intravenous bone targeting agent (Calcium mimic) carrying a localised radioactive isotope (alpha emitter). It is given in 6 injections monthly. Side effects very few.
30 30 Metastatic disease LHRH analogues Consider Casodex withdrawal, stilboestrol, steroids Add antiandrogens Abiraterone Docetaxel Cabazitaxel
31 31 Metastatic disease LHRH analogues Add antiandrogens Consider Casodex withdrawal, stilboestrol, steroids Radium 223 Docetaxel Abiraterone Enzalutamide Cabazitaxel
32 32 Metastatic disease LHRH analogues Add antiandrogens Consider Casodex withdrawal, stilboestrol, steroids Radium 223 Docetaxel Abiraterone Enzalutamide Cabazitaxel
33 33 Optimal sequencing of agents Unknown
34 34
35 35 Biomarkers which might help us in the future Androgen receptor mutations (eg AR-V7) Circulating tumour DNA
36 36 A sensible sequence of treatments might be Castration sensitive LHRHa plus docetaxel if fit (LHRH alone if not) Castration resistance When PSA fails, add bicalutamide 50mg od When PSA fails, withdraw bicalutamide (? Response) Bicalutamide withdrawal response?
37 37 A sensible sequence of treatments might be (part 2) When PSA fails, add dexamethasone 0.5mg od (nongonadal androgens) if frail or abiraterone/enzalutamide if fit, or Radium for boneonly disease For fit patients, consider Cabazitaxel or rechallenge with Docetaxel.
38 38 Common symptoms and palliation
39 39 Zoledronic acid Randomised trials vs placebo: Zoledronic acid delayed time to SRE (039 trial, Saad et al, JNCI 2002, 2004) No survival advantage,? Detriment in QOL Not recommended for SRE prophylaxis except in osteoporosis (ADT) or with (rare) lytic metastases.
40 40 Denosumab vs Zoledronic acid Human monoclonal antibody vs RANKL (inhibits osteoclasts) No OS advantage Fizazi et al Lancet 2011
41 41 Spinal cord compression Majority of radiotherapy emergencies Common complication of metastatic cancer 2.5 5% of all terminal cancer patients in last 2 years of life May also be presenting symptom (0.23% of cancer patients)
42 Pathophysiology
43 43
44 Pathophysiology
45 Pathophysiology Extrinsic Compression Bone metastases enlarge and press on thecal sac Para-spinal tumour growth through neural foramina Destruction of cortical bone causing collapse and retropulsion of bony fragments Cord damage from oedema, axonal swelling and ischaemia necrosis
46 Site of compression Thoracic 60-80% Lumbosacral 15-30% Cervical <10% Up to 50% have multiple levels of involvement
47 Symptoms and Signs Pain Gait ataxia early sign Motor deficits Sensory deficits Autonomic dysfunction Can be difficult to distinguish from signs of general deterioration
48 48 Urgent MRI of WHOLE SPINE Delay in diagnosis and appropriate treatment leads to worsen neurological prognosis (and survival)
49 Cauda Equina Lesions below conus / at nerve roots Tend to be associated with lumbo sacral pain Radicular pain and lateralising signs and distal weakness commoner Urinary retention, constipation or impotence suspicious if new onset Reflexes lost in nerve root group
50 Grading Power (MRC) Grade 0 no muscle action Grade 1 muscles seen to contract but no movement Grade 2 movement occurs if gravity eliminated Grade 3 movement against gravity Grade 4 movement against up to 75% resistance Grade 5 movement against gravity and maximal resistance
51 51 Mandatory cord compression pathway Referral form to neurosurgical centre Dex 8mg bd with PPI cover Cases then discussed with a neurosurgeon (better functional outcome) If not for neurosurgery needs urgent radiotherapy Usually 20 Gy in 5 fractions daily over one week Wean off steroids once RT complete
52 52 Bone metastases Most metastatic prostate patients Can cause pain Palliative radiotherapy very effective 60-70% response of pain Around a third have a pain flare 1-3 days after RT
53 53 What dose for bone mets? 20 Gy in 5 fractions = 8 Gray in one fraction Yarnold et al, Radiother Oncol, 1999
54 54 Higher rate of pain recurrence with 8 Gy can repeat
55 55 Lymph node metastases Role of palliative radiotherapy Not often painful Lymphoedema of limbs due to lymphatic obstruction
56 56 Summary Lots of new therapies over the last 5 years All prolong survival metastatic prostate cancer survival now >5 years Optimal sequencing unknown Symptomatic complications common
57 57 Any questions?
Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S
Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia Meet Mr. S 74 M admitted for back pain X-ray: sclerotic lesions along spine PSA 800 Nuclear Medicine Bone Scan 1
More informationFirst-line Hormone Therapy
First-line Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationManagement of spinal cord compression
Management of spinal cord compression (SUMMARY) Main points a) On diagnosis, all patients should receive dexamethasone 10mg IV one dose, then 4mg every 6h. then switched to oral dose and tapered as tolerated
More informationMALIGNANT SPINAL CORD COMPRESSION. Kate Hamilton Head of Medical Oncology Ballarat Health Services
MALIGNANT SPINAL CORD COMPRESSION Kate Hamilton Head of Medical Oncology Ballarat Health Services OVERVIEW Background Epidemiology Pathophysiology Diagnosis Investigation Differential Diagnosis Management
More informationUpdates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015.
Updates in Prostate Cancer Therapy Sequencing Strategies Debates and Didactics in Hematology and Oncology July 26, 2015. Sea Island, GA Bradley C. Carthon, MD. Ph.D. Assistant Professor, Winship Cancer
More informationIssues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
More informationSIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
More informationEstablishing an Advanced Prostate Cancer Clinic: The Rationale
The information, views and opinions expressed in this presentation and any accompanying materials are those of the speaker and do not necessarily reflect the views or position of Cardinal Health or VitalSource.
More informationTHE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE
THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE Summary of Presentations from the Bayer Healthcare Symposium, held at the 29 th Annual EAU
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationHormonal therapy for advanced prostate cancer
Hormonal therapy for advanced prostate cancer This information is an extract from the booklet Understanding advanced (metastatic) prostate cancer. You may find the full booklet helpful. We can send you
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationEvaluation of Treatment Pathways in Oncology: An Example in mcrpc
Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Sonja Sorensen, MPH United BioSource Corporation Bethesda, MD 1 Objectives Illustrate selection of modeling approach for evaluating pathways
More informationAdvanced prostate cancer
1 Advanced prostate cancer In this fact sheet: What is advanced (metastatic) prostate cancer? What tests are used to diagnose advanced prostate cancer? What do my test results mean? What are my treatment
More informationProstate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment
Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment Abstract Prostate is one of the most commonly diagnosed solid tumours in males worldwide. Selection of
More informationPatient & Family Guide 2015 Hormone Therapy for Prostate Cancer
Patient & Family Guide 2015 Hormone Therapy for Prostate Cancer www.nshealth.ca Hormone Therapy for Prostate Cancer What is the prostate? The prostate is one of the male sex glands. It makes seminal fluid
More informationAdvanced prostate cancer
Diagnosis Helpline 0800 074 8383 prostatecanceruk.org 1 Advanced prostate cancer In this fact sheet: What is advanced (metastatic) prostate cancer? What tests are used to diagnose advanced prostate cancer?
More informationMetastatic Prostate Cancer
Patient Information English 35 Metastatic Prostate Cancer The underlined terms are listed in the glossary. Prostate cancer can spread to other organs or lymph nodes outside the pelvic area. This is called
More information2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL. Howard R. Soule, PhD
2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL Howard R. Soule, PhD 1 May 29-June 2, 2015 Chicago, IL Theme: Illumination and Innovation Transforming Data Into Learning We
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationIncorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice
Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Please see Important Safety Information throughout this presentation and full Prescribing Information available at this 2014 Bayer
More informationPROSTATE CANCER. Learning Objectives. Question 4/3/2014
PROSTATE CANCER Lindsay Kaster, PharmD Clinical Oncology Pharmacist Boise VA Medical Center Learning Objectives Discuss the cancer diagnosis and screening, including the role of Prostate Specific Antigen
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationTraitement médical du Cancer de la Prostate: du désert à la profusion. Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Traitement médical du Cancer de la Prostate: du désert à la profusion Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for:
More informationTreatment of metastatic prostate cancer CLARE GILSON, THUBEENA MANICKAVASAGAR AND SIMON CHOWDHURY
7 Treatment of metastatic prostate cancer CLE GILSON, THUBEENA MANICKAVASAG AND SIMON CHOWDHURY The authors review the current therapeutic approaches and consider the many remaining questions and challenges
More informationUniversity College Hospital. Hormone therapy for prostate cancer. Radiotherapy Department Patient information series
University College Hospital Hormone therapy for prostate cancer Radiotherapy Department Patient information series 10 2 If you need a large print, audio or translated copy of the document, please contact
More informationBreast Cancer. Breast Cancer Page 1
Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or
More informationWhat You Need to Know for Better Bone Health
What You Need to Know for Better Bone Health A quick lesson about bones: Why healthy bones matter The healthier your bones The more active you can be Bone health has a major effect on your quality of life
More informationWhat s new in prostate cancer research? Highlights of GU-ASCO 2014
review What s new in prostate cancer research? Highlights of GU-ASCO 2014 Cite as: Can Urol Assoc J 2014;8(3-4Suppl2):S8-12. http://dx.doi.org/10.5489/cuaj.2013 Published online April 14, 2014. Abstract
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More informationPeople Living with Cancer
Patient Guide ASCOInformation for People Living with Cancer HORMONE THERAPY FOR ADVANCED PROSTATE CANCER Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical
More informationMalignant Spinal Cord Compression: Highlights on Specific Management Aspects
Palliative Medicine Doctors Meeting HKSPM Newsletter 2008 Apr Issue 1 p 21 Malignant Spinal Cord Compression: Highlights on Specific Management Aspects Dr. KH Wong Department of Clinical Oncology, Queen
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationAdvanced prostate cancer
Diagnosis Specialist Nurses 0800 074 8383 prostatecanceruk.org 1 Advanced prostate cancer In this fact sheet: What is advanced prostate cancer? How is advanced prostate cancer diagnosed? What do my test
More informationClinical guideline Published: 8 January 2014 nice.org.uk/guidance/cg175
Prostate cancer: diagnosis and management Clinical guideline Published: 8 January 2014 nice.org.uk/guidance/cg175 NICE 2014. All rights reserved. Contents Introduction... 4 Drug recommendations... 5 Patient-centred
More informationProstate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).
Prostate Cancer Definition Prostate cancer is cancer that starts in the prostate gland. The prostate is a small, walnut-sized structure that makes up part of a man's reproductive system. It wraps around
More informationMetastatic Prostate Cancer
CANCERCARE CONNECT BOOKLET SERIES Treatment Update Metastatic Prostate Cancer www.cancercare.org The CancerCare Connect Booklet Series offers up-to-date, easy-to-read information on the latest treatments,
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationDIAGNOSIS OF PROSTATE CANCER
DIAGNOSIS OF PROSTATE CANCER Determining the presence of prostate cancer generally involves a series of tests and exams. Before starting the testing process, the physician will ask questions about the
More informationWhat is prostate cancer?
Prostate Cancer What is prostate cancer? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines PROSTATE CANCER: A GUIDE
More informationWHAT TO EXPECT FROM YOUR TREATMENT. Please see accompanying full Prescribing Information and Important Safety Information on page 14.
WHAT TO EXPECT FROM YOUR TREATMENT Please see accompanying full Prescribing Information and Important Safety Information on page 14. Please see accompanying full Prescribing Information and Important Safety
More informationDrug costs in the management of metastatic castration-resistant prostate cancer in Canada
Dragomir et al. BMC Health Services Research 2014, 14:252 RESEARCH ARTICLE Drug costs in the management of metastatic castration-resistant prostate cancer in Canada Alice Dragomir 1,2*, Daniela Dinea 1,3,
More informationNHS England Reference: [B15/PS/a]
Clinical Commissioning Policy Statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer NHS England Reference: [B15/PS/a] NHS England
More informationA rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml
IJCRI 2011;2(9):16-20. Rajendiran et al. 16 CASE REPORT OPEN ACCESS A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml Govarthanan Rajendiran, Linda Green,
More informationAmerican Urological Association (AUA) Guideline
1 Approved by the AUA Board of Directors April 2015 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2015 by the American Urological
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationX-Plain Low Testosterone Reference Summary
X-Plain Low Testosterone Reference Summary Introduction Testosterone is the most important male sex hormone. It helps the body produce and maintain adult male features. Low levels of testosterone affect
More informationBone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationPRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme)
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationProstate Cancer. Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute
Prostate Cancer Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute 1 Educational Objectives By the end of this session, participants should be able to Understand
More informationWHAT TO EXPECT FROM YOUR TREATMENT
WHAT TO EXPECT FROM YOUR TREATMENT FIRMAGON is a prescription medicine used in the treatment of advanced prostate cancer. INTRODUCTION This brochure will help prepare you for your FIRMAGON (degarelix for
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationProstate Cancer Studies
Prostate Cancer Studies STUDIES CURRENTLY RECRUITING MDV3100-14 A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastic
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationUrology Nurse Practitioner Urology Research Nurse Australian Prostate Cancer Research Centre Epworth November 18, 2011
Urology Nurse Practitioner Helen Crowe Urology Nurse Practitioner Urology Research Nurse Australian Prostate Cancer Research Centre Epworth November 18, 2011 Nurse Practitioner Registered nurse who has
More informationClinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
More informationDepartment of Clinical Effectiveness V10 Approved by the Executive Committee of the Medical Staff 10/28/2014
te: Consider Clinical Trials as treatment options for eligible patients. This Prostate Cancer treatment consensus algorithm is used as a framework for the application of individualized therapy for patients
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationOne out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
More information4.2 Spinal Cord Compression
4.2 Spinal Cord Compression AO Protocol Name: Metastatic Spinal Cord Compression (MSCC) AO Type: Type I (New Cancer), Type III (Cancer Complication) Author: ST Introduction: MSCC can cause irreversible
More informationPROSTATE CANCER. Effective Date: March, 2015
PROSTATE CANCER Effective Date: March, 2015 The recommendations contained in this guideline are a consensus of the Alberta Provincial Genitourinary Tumour Team and are a synthesis of currently accepted
More informationWHEN PROSTATE CANCER RETURNS: ADVANCED PROSTATE CANCER. How Will I Know If My Prostate Cancer Returns?
WHEN PROSTATE CANCER RETURNS: ADVANCED PROSTATE CANCER (The following information is based on the general experiences of many prostate cancer patients. Your experience may be different.) How Will I Know
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationRadiation Therapy for Prostate Cancer
Radiation Therapy for Prostate Cancer Introduction Cancer of the prostate is the most common form of cancer that affects men. About 240,000 American men are diagnosed with prostate cancer every year. Your
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationBone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationStage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
More informationUniversity College Hospital. Metastatic spinal cord compression (MSCC) information for patients at risk of developing MSCC.
University College Hospital Metastatic spinal cord compression (MSCC) information for patients at risk of developing MSCC Cancer Services 2 If you would like this document in another language or format,
More informationMANAGING ADVANCED PROSTATE CANCER
MANAGING ADVANCED PROSTATE CANCER WHAT IS? Whether you ve been living with prostate cancer for years or newly diagnosed, you have advanced prostate cancer when cancer cells have: 1. Spread outside the
More informationHormone therapy. In this fact sheet: How does hormone therapy treat prostate cancer? What happens next?
1 Hormone therapy In this fact sheet: How does hormone therapy treat prostate cancer? Who can have hormone therapy? What types of hormone therapy are there? What are the advantages and disadvantages of
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM G.R. Dohle (chair), S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationSupportive Care For Patients With High-Grade Glioma (primary brain tumours) Dr Susan Catt & Professor Lesley Fallowfield
Supportive Care For Patients With High-Grade Glioma (primary brain tumours) Dr Susan Catt & Professor Lesley Fallowfield Partners Mr Giles Critchley Consultant Neurosurgeon Hurstwood Park Neurological
More informationHormone Therapy for Prostate Cancer A Patient Guide
Your Health Matters Hormone Therapy for Prostate Cancer A Patient Guide Urologic Oncology Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco Phone number:
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationPalliative Radiation. Dr. G. Schroeder
Palliative Radiation Dr. G. Schroeder Indications for Palliative Radiation Pain Control Bone Metastases Pressure of tumour on nerves Relief of Superior Vena Obstruction Spinal Cord Compression Bleeding
More informationPROSTATE CANCER NOT TO BE TAKEN LIGHTLY!
PROSTATE CANCER NOT TO BE TAKEN LIGHTLY! Observations of Wichita Chapter Us TOO Members through research, reading p2p (physician to patient) exchanges, or having attended or reviewed recordings of presentations
More informationClinical Practice Guidelines for the management of locally advanced and metastatic prostate cancer
Clinical Practice Guidelines for the management of locally advanced and metastatic prostate cancer www.cancer.org.au Clinical Practice Guidelines for the management of locally advanced and metastatic prostate
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationInhibition de MET et cancer(s) de la prostate
Inhibition de MET et cancer(s) de la prostate Dr Christophe Massard Institut Gustave Roussy, Department of Cancer Medicine christophe.massard@igr.fr FOM 2013, Lille Session Nouvelles molécules - Vendredi
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More informationCycle frequency: Every three weeks Total number of cycles: 3 or 4
BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs
More informationProstate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
More informationRadiotherapy in Plasmacytoma and Myeloma. David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015
Radiotherapy in Plasmacytoma and Myeloma David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015 Contents Indications for radiotherapy: Palliation in Multiple Myeloma Solitary Bone Plasmacytoma
More informationRT for Recurrent, Bulky, and Chemotherapy-Refractory Follicular Lymphoma: A Treatment Modality for Both Alleviating Symptoms and Potential Cure
RT for Recurrent, Bulky, and Chemotherapy-Refractory Follicular Lymphoma: A Treatment Modality for Both Alleviating Symptoms and Potential Cure Case Number: RT2009-04(M) Potential Audiences: Intent Doctor,
More informationRoswell Park scientists and clinicians:
The Prostate Cancer Center at Roswell Park Connects You to Nationally Recognized Experts for State-of-the-Art Treatment Options and Compassionate, Evidence-based Care Founded in 1898, Roswell Park Cancer
More informationBasics on Treatment for prostate cancer
Basics on Treatment for prostate cancer SECTION 1: TREATMENTS This pamphlet provides information about different treatments for prostate cancer including what to expect and any risks and side-effects.
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationProstate Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology
Prostate Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO The American Society of Clinical Oncology (ASCO) is the world s leading professional
More informationParaneoplastic Antibodies in Clinical Practice. Mohammed El lahawi New Cross Hospital Wolverhampton
Paraneoplastic Antibodies in Clinical Practice Mohammed El lahawi New Cross Hospital Wolverhampton 1 Effects of Neoplasm Direct mass ( pressure ) effect Metastasis effect Remote effect 2 The Nervous System
More informationBrain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.
Brain Cancer Introduction Brain tumors are not rare. Thousands of people are diagnosed every year with tumors of the brain and the rest of the nervous system. The diagnosis and treatment of brain tumors
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationGUIDELINES FOR ASSESSMENT OF SPINAL STABILITY THE CHRISTIE, GREATER MANCHESTER & CHESHIRE. CP57 Version: V3
GUIDELINES FOR ASSESSMENT OF SPINAL STABILITY THE CHRISTIE, GREATER MANCHESTER & CHESHIRE Procedure Reference: Document Owner: CP57 Version: V3 Dr V. Misra Accountable Committee: Acute Oncology Group Network
More informationMetastatic Breast Cancer: The Art and Science of Systemic Therapy. Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba
Metastatic Breast Cancer: The Art and Science of Systemic Therapy Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba Presenter Disclosure Faculty: Dr. Vallerie Gordon Relationships with commercial
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More information